BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that updated clinical data from an ongoing Phase 1 A/1B trial of tislelizumab, an investigational anti-PD-1 antibody, were presented in an oral...
"Lung cancer is the highest incidence cancer in China, and bevacizumab is an important treatment for non-small lung cancer patients. The launch of a high-quality bevacizumab biosimilar will improve drug accessibility and benefit more patients, "said Li Zhang, MD, from the cancer hospital of Sun Yat-Sen University, in a statement announcing the posi
Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:. -If approved, this will add to the five existing VTE indications for XARELTO (R)- the most studied anticoagulant available to the most groups of patients. The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the submission
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal second quarter ended October 31, 2018. We are still on track with our robust Phase 2 study for
Paradigm Biopharmaceuticals Ltd is in a trading halt with results pending for the companys Phase 2 b placebo-controlled OA/BMEL clinical trial. Shares last traded at $1.32 after reaching a new 12- month high of $1.63 earlier this month. Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form, a US Food and Dru
Pfizer, a pharmaceutical company, issued the following news release:. Pfizer Inc. announced today the initiation of a Phase 3 program for its 20- Valent pneumococcal conjugate vaccine candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and o
Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending marketing authorization for ZIRABEV (TM), a potential biosimilar to Avastin. 1 ZIRABEV is a monoclonal antibody for the treatment of metastatic carcinoma of the colon or rectum, metastatic
-If Authorized in Europe, ADCETRIS in Combination with AVD Will Be the First New Treatment Regimen Available for Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Decades. Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a posi
Today`s Daily Dose brings you news about disappointing trial results of Applied Genetic Technologies; near-term catalyst of Idera; stock offering of Marinus; disappointing Tourette syndrome trial results of Neurocrine Biosciences; bankruptcy proceedings of Synergy Pharma; Complete Response Letter for Mallinckrodt`s pain drug, and promising data fro
AMAG Pharmaceuticals, Inc. today announced it has entered into a definitive agreement to acquire Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Ciraparantag has been granted Fast Track review designation by the U.S. Food and Drug Administration and has patent protection through 2034.. NOAC therapy represents the...
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system diseases, today reported financial results for its fiscal year...
via NEWMEDIAWIRE AngioSoma, Inc. announced today the Company has entered into a partially binding letter of intent to acquire 100% of the equity interests in Diabetes Relief LLC. Gross revenue of Diabetes Relief for the current year is forecasted to be $2,416,716, for the prior year $1,900,944, and for 2015 was $213,434. The following statement
-Aptevo Therapeutics Inc., a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the first patient has been dosed in a Phase 1/ 1 b clinical trial of APVO436, a novel anti-CD123 by anti-CD3 bispecific antibody based on Aptevos ADAPTIR technology, which is being developed for the treatment of
The R&D team at Bio-Rad AbD Serotec in Munich has developed a new type of specific antibodies. Attana's technology was applied to select and optimize the best of these new antibodies. Attana's technology has been applied to develop the desired interaction profile of these typ 3 antibodies to secure a high specificity and interaction properties.
Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported safety and promising activity of BPX-601 in Part 1 of a Phase 1/ 2 dose-escalation study in patients with advanced, metastatic pancreatic cancer expressing PSCA. Data were reviewed du
Applied Genetic Technologies Corp. said late Wednesday that Biogen Inc. terminated the companies' gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was down $3.09 to $3.47 on Thursday. The deal included $124 million up front comprising $94 million in licensing fees
BioLineRx announced today that it has initiated a new arm of its Phase 2 a study involving the triple combination of its lead compound, BL-8040, with Merck`s Keytruda and chemotherapy, in patients with metastatic pancreatic cancer. The company refers to this as "transforming science into medicine" and has collaborative agreements with Merck and Gen
INCHEON, South Korea& JERUSALEM Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved HERZUMA , a HER2/neu receptor antagonist biosimilar to HERCEPTIN 1 for the following indications:. Biosimilars are of growing importance to the oncology community and the approva
Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for Nplate for the treatment of pediatric patients one year of age and older with immune thrombocytopenia for at least six months who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Agency: " Food and Drug Administration, HHS." SUMMARY: The Food and Drug Administration is announcing the withdrawal of the proposed rule on "Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products" that published in the Federal Register of November 13, 2013. FDA is taking this action in light of concerns exp
Generex Biotechnology Corporation announced today that Regentys Corporation, a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted European Patent No. 2983616 entitled Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.. This specific patent provides exclusive ma
Generex Biotechnology Corporation today announced that the FDA had reviewed the companys investigational new drug application and given notification that the study can proceed. The study: A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer, is sponsored by
Supplemental new drug application submitted in Japan for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant Submission based on data from Phase III ALCYONE study Genmab to receive USD 2 million milestone payment from.
Gibson Oncology, LLC, a privately held clinical stage company developing a novel class of oncology drugs for treating adult and pediatric cancers resistant to traditional cancer drugs, announced today that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to LMP-400, Gibsons novel small molecule topoisomerase 1...
Glenmark Pharmaceuticals, a global innovative pharmaceutical company, today announced the presentation of new pharmacokinetic data from the ongoing Phase 1 trial of GBR 1302, a HER2xCD3 bispecific antibody, at the European Society for Medical Oncology Immuno-Oncology Congress 2018 in Geneva, Switzerland. GBR 1302 is Glenmark's lead immuno-oncolog